With the recent breakthroughs in machine learning and the mass digitization of medical data, the world of medicine is entering into a new era of data-driven medicine. However, despite the advancements, nearly 30% of lung cancer and breast cancer cases currently go unidentified and misdiagnosed. To solve this problem, Minhong co-founded Lunit in 2013, which develops AI solutions for precision diagnostics and therapeutics - finding the right diagnosis at the right cost and the right treatment for the right patients. Lunit aims to make data-driven medicine the new standard of care. It is especially focused on conquering cancer - one of the leading causes of death worldwide.
Lunit has been internationally acknowledged for its advanced, state-of-the-art technology. Its application in medical images has been named by CB Insights as one of "AI 100" startups transforming the healthcare industry and has also been nominated as a "Digital Health 150" company. Moreover, Lunit has been chosen by the World Economic Forum as one of the "Technology Pioneers" that shape the future. Through these achievements, Lunit has raised more than $84 million from notable companies in the China, Japan, Korea, and the US. Minhong currently leads Lunit’s solution business for radiology and has spearheaded partnerships with medical imaging technology leaders such as GE Healthcare, Philips, and FujiFilm. As a result, more than 400 hospitals in over 30 countries are using Lunit’s solution in their day-to-day clinical workflows for better patient care.
Through their unprecedented AI technology, Lunit seeks to provide AI solutions that open a new era of data-driven precision medicine. By implementing AI solutions for diagnostic and therapeutic biomarkers, Lunit aims to solve the most critical issues in cancer care today: reduce medical costs and prolong survival.